In Germany, women with newly identified BRCA1 or BRCA2 variants receive individual care and counseling on their genetic findings, cancer risks, and preventive options at the centers of the German Consortium of Familial Breast and Ovarian Cancer (GC-HBOC). This evidence concerns the gene BRCA2 and ovarian carcinoma.